We envision a world without a risk for renal toxicity for compounds entering clinical stages of drug development. Cell4Pharma aims to reduce the failure rate in late clinical stages due to renal tox below 3% market wide within the next 10 years. Without the use of animal experimentation. This ambition is supported by our human renal cell line ciPTEC validated during extensive collaborations with the pharmaceutical industry. More than 10 years of research lead to the development of robust cell-based assays focusing on the detection of highly specific biomarkers for renal toxicity.
View Top Employees from Cell4PharmaWebsite | https://www.cell4pharma.com/ |
Revenue | $3 million |
Employees | 9 (4 on RocketReach) |
Phone | +31 6 22351074 |
Technologies |
JavaScript,
HTML,
PHP
+5 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Business Services |
SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 80 Companies |
NAICS | NAICS Code 62151 Companies, NAICS Code 6215 Companies, NAICS Code 621 Companies, NAICS Code 62 Companies |
Looking for a particular Cell4Pharma employee's phone or email?
The Cell4Pharma annual revenue was $3 million in 2024.
Ron Byron is the Managing Director of Cell4Pharma.
4 people are employed at Cell4Pharma.
The NAICS codes for Cell4Pharma are [62151, 6215, 621, 62].
The SIC codes for Cell4Pharma are [283, 28, 80].